Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Inter-individual courses of multiple sclerosis (MS) are extremely variable. The objective of this study was to investigate whether κ-free light chain (κ-FLC) index and serum neurofilament light (sNfL) have an additive predictive value for MS disease activity.
Methods: Patients with early MS who had cerebrospinal fluid (CSF) and serum sampling at disease onset were followed for four years. At baseline, age, sex, disease duration, number of T2-hyperintense (T2L), and contrast-enhancing T1 lesions (CEL) on MRI were determined. During follow-up, the occurrence of a second clinical attack and start of disease-modifying treatment (DMT) were registered. κ-FLC was measured by nephelometry, and κ-FLC index calculated as [CSF κ-FLC/serum κ-FLC]/albumin quotient. sNfL was determined by single-molecule array, and age- and body-mass-index adjusted Z scores were calculated.
Findings: A total of 86 patients at a mean age of 33 ± 10 years and with a female predominance of 67% were included; 36 (42%) patients experienced a second clinical attack during follow-up. Cox regression analysis adjusted for age, sex, T2L, CEL, disease and follow-up duration, and DMT use during follow-up revealed that both κ-FLC index as well as sNfL Z score independently predict time to second clinical attack. The chance for freedom of relapse within 12 months was 2% in patients with high levels of κ-FLC index (>100) and high sNfL Z score (>3), 30% in patients with high κ-FLC index (>100) and lower sNfL Z score (≤3), 70% in patients with lower κ-FLC index (≤100) but high sNfL Z score (>3), and 90% in patients with lower levels of κ-FLC index (≤100) and sNfL Z score (≤3).
Interpretation: κ-FLC index and sNfL Z score have an additive predictive value for early MS disease activity that is independent of known predictors.
Funding: This study was funded by a grant of the charitable foundation of the Austrian Multiple Sclerosis Society.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148088 | PMC |
| http://dx.doi.org/10.1016/j.ebiom.2023.104573 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rett Syndrome: Specific MECP2 Variants are Associated With Elevated Serum Neurofilament Light Chain.
Pediatr Neurol
August 2025
Department of Neuropediatrics, Jena University Hospital, Jena, Germany; Center for Rare Diseases, Jena University Hospital, Jena, Germany. Electronic address:
Background: Rett syndrome, a neurodevelopmental disorder predominantly affecting females, is caused by variants in MECP2. Individuals experience a decline in skills, particularly involving language and hand function; nevertheless, studies of brain pathology suggest that neurodegeneration is not involved. To further investigate the presence of neurodegeneration, we measured serum neurofilament light chain (sNfL), a sensitive biomarker of neuronal damage.
View Article and Find Full Text PDFSerum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosis.
Mult Scler
August 2025
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Background: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers of axonal damage and astrocytic activation. The value of sNfL and GFAP in predicting retinal layer thinning remains underexplored.
Objectives: To evaluate the association between sNfL and GFAP levels and retinal layer thinning.
Blood metabolomics improves prediction of central nervous system damage in multiple sclerosis.
Metabolomics
August 2025
Laboratories of Neuroimmunology, Department of Clinical Neurosciences, Center for Research in Neuroscience and Service of Neurology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Introduction: Multiple sclerosis (MS) is an autoimmune disorder with an unpredictable outcome at the time of diagnosis. The measurement of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) has introduced new biomarkers for assessing MS disease activity and progression. However, there is a need for additional diagnostic and prognostic tools.
View Article and Find Full Text PDFSeverity-Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19-Targeted CAR T-Cell Therapy.
Eur J Neurol
August 2025
Department of Neurology and MS Centre of Catalonia (Cemcat), Vall D'hebron University Hospital, Barcelona, Spain.
Background And Objectives: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a potential complication following Chimeric Antigen Receptor (CAR) T-cell infusion. Biomarkers to aid in early diagnosis and severity assessment are lacking. We aim to describe and compare serum neurofilament light chain (sNfL) dynamics in non-Hodgkin lymphoma (NHL) patients undergoing anti-CD19 CAR T-cell therapy, based on ICANS presence and severity.
View Article and Find Full Text PDFNeurologists' Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants.
Neuropsychiatr Dis Treat
July 2025
Medical Department, Roche Farma, Madrid, Spain.
Purpose: Integration of evidence-based innovations, such as serum neurofilament light chain (sNfL) measurement into routine practice represents a pivotal opportunity to advance personalized care in multiple sclerosis (MS) management. This study assessed neurologists' openness to adopting healthcare innovations (sNfL testing), focusing on individual characteristics and structural factors like workplace environment and resources.
Methods: An observational, cross-sectional study was conducted in partnership with the Spanish Society of Neurology.